• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(S)-卡维地洛盐的最优形式的制备、表征和选择,用于开发缓释制剂。

Preparation, Characterization, and Selection of Optimal Forms of (S)-Carvedilol Salts for the Development of Extended-Release Formulation.

机构信息

Institute of Materia Medica, Hangzhou Medical College, 310013 Hangzhou, China.

NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, 510515 Guangzhou, China.

出版信息

Mol Pharm. 2021 Jun 7;18(6):2298-2310. doi: 10.1021/acs.molpharmaceut.1c00100. Epub 2021 May 25.

DOI:10.1021/acs.molpharmaceut.1c00100
PMID:34032449
Abstract

(S)-carvedilol (S-CAR) is the dominant pharmacodynamic conformation of carvedilol, but its further development for extended-release formulation is restricted by its poor solubility. This study aimed to prepare and screen S-CAR salts that could be used to improve solubility and allow extended release. Five salts of S-CAR with well-known acid counterions (, phosphate, hydrochloride, sulfate, fumarate, and tartrate) were produced using similar processes. However, these salts were obtained with water contents of 1.60-12.28%, and their physicochemical properties differed. The melting points of phosphate, hydrochloride, and tartrate were 1.1-1.5 times higher than that of the free base. The solubility of S-CAR salts was promoted to approximately 3-32 times higher than that of the free base at pH 5.0-8.0. Typical pH-dependent solubilities were evidently observed in S-CAR salts, but considerable differences in solubility properties among these salts were observed. S-CAR phosphate and hydrochloride possessed high melting points, considerable solubility, and excellent chemical and crystallographic stabilities. Accordingly, S-CAR phosphate and hydrochloride were chosen for further pharmacokinetic experiments and pharmaceutical study. S-CAR phosphate and hydrochloride extended-release capsules were prepared using HPMC K15 as the matrix and presented extended release in and evaluations. Results implied that water molecules in the hydrated salt were a potential threat to the achievement of crystal stability and thermostability. S-CAR phosphate and hydrochloride are suitable for further development of the extended-release formulation.

摘要

(S)-卡维地洛(S-CAR)是卡维地洛的主要药效构象,但由于其溶解度差,其进一步开发为缓释制剂受到限制。本研究旨在制备和筛选可用于提高溶解度并允许延长释放的 S-CAR 盐。使用相似的方法生产了具有知名酸反离子(磷酸盐、盐酸盐、硫酸盐、富马酸盐和酒石酸盐)的五种 S-CAR 盐。然而,这些盐的含水量为 1.60-12.28%,其物理化学性质不同。磷酸盐、盐酸盐和酒石酸盐的熔点比游离碱高 1.1-1.5 倍。S-CAR 盐在 pH 5.0-8.0 下的溶解度提高到游离碱的约 3-32 倍。在 S-CAR 盐中明显观察到典型的 pH 依赖性溶解度,但这些盐之间的溶解度性质存在很大差异。S-CAR 磷酸盐和盐酸盐具有较高的熔点、较大的溶解度以及良好的化学和结晶稳定性。因此,选择 S-CAR 磷酸盐和盐酸盐进行进一步的药代动力学实验和药物研究。使用 HPMC K15 作为基质制备了 S-CAR 磷酸盐和盐酸盐缓释胶囊,并在 和 评估中呈现了缓释效果。结果表明,水合盐中的水分子可能对晶体稳定性和热稳定性的实现构成威胁。S-CAR 磷酸盐和盐酸盐适合进一步开发缓释制剂。

相似文献

1
Preparation, Characterization, and Selection of Optimal Forms of (S)-Carvedilol Salts for the Development of Extended-Release Formulation.(S)-卡维地洛盐的最优形式的制备、表征和选择,用于开发缓释制剂。
Mol Pharm. 2021 Jun 7;18(6):2298-2310. doi: 10.1021/acs.molpharmaceut.1c00100. Epub 2021 May 25.
2
Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study.壳聚糖纳米粒增强难溶性卡维地洛的口服生物利用度:优化及药代动力学研究。
Int J Biol Macromol. 2019 Aug 15;135:246-260. doi: 10.1016/j.ijbiomac.2019.05.162. Epub 2019 May 23.
3
Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.新型快速合成中空介孔硅纳米粒子(HMSNs)的方案及其作为改善难溶性 BCS Ⅱ类药物口服生物利用度的有效递送载体的应用。
Colloids Surf B Biointerfaces. 2019 Apr 1;176:185-193. doi: 10.1016/j.colsurfb.2019.01.004. Epub 2019 Jan 2.
4
Optimization of lipid materials in the formulation of S-carvedilol self-microemulsifying drug-delivery systems.S-卡维地洛自微乳化药物递送系统制剂中脂质材料的优化
Drug Dev Ind Pharm. 2020 Sep;46(9):1507-1516. doi: 10.1080/03639045.2020.1810265. Epub 2020 Aug 27.
5
Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol.制备新型转基因生物/丙烯酸树脂E100纳米结构以提高卡维地洛的口服生物利用度。
Drug Dev Ind Pharm. 2016 Aug;42(8):1300-7. doi: 10.3109/03639045.2015.1128440. Epub 2016 Jan 6.
6
The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release.
Drug Dev Ind Pharm. 2017 Mar;43(3):421-431. doi: 10.1080/03639045.2016.1257019. Epub 2016 Nov 21.
7
Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.应用统计工具技术设计卡维地洛纳米脂质体及其皮肤药代动力学和药效学研究。
Pharm Nanotechnol. 2020;8(6):452-470. doi: 10.2174/2211738508666200928164820.
8
Novel carvedilol paediatric nanomicelle formulation: in-vitro characterization and in-vivo evaluation.新型卡维地洛儿科纳米胶束制剂:体外表征与体内评价。
J Pharm Pharmacol. 2017 May;69(5):544-553. doi: 10.1111/jphp.12605. Epub 2016 Jul 19.
9
Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?脂肪对犬体内卡维地洛吸收的影响:与脂肪制剂相比,同时给予脂肪是否同样有效?
J Control Release. 2019 Jun 28;304:90-100. doi: 10.1016/j.jconrel.2019.04.038. Epub 2019 Apr 29.
10
Improvement of oral bioavailability of carvedilol by liquisolid compact: optimization and pharmacokinetic study.采用液质联用技术优化并考察卡维地洛固体自微乳制剂的相对生物利用度。
Drug Deliv Transl Res. 2020 Aug;10(4):975-985. doi: 10.1007/s13346-020-00734-3.

引用本文的文献

1
The Incorporated Drug Affects the Properties of Hydrophilic Nanofibers.掺入的药物会影响亲水性纳米纤维的性质。
Nanomaterials (Basel). 2024 May 28;14(11):949. doi: 10.3390/nano14110949.